claim: The Group of 15 includes Chile.
evidence: Pimavanserin -LRB- INN -RRB- , or pimavanserin tartate -LRB- USAN -RRB- , marketed under the trade name Nuplazid ' , is a non-dopaminergic atypical antipsychotic developed by Acadia Pharmaceuticals for the treatment of Parkinson 's disease psychosis and schizophrenia .. INN. International Nonproprietary Name. USAN. United States Adopted Name. dopaminergic. dopaminergic. atypical antipsychotic. atypical antipsychotic. Acadia Pharmaceuticals. Acadia Pharmaceuticals. psychosis. psychosis. schizophrenia. schizophrenia. antipsychotic. antipsychotic. Pimavanserin has a unique mechanism of action relative to other antipsychotics , behaving as a selective inverse agonist of the serotonin 5-HT2A receptor , with 40-fold selectivity for this site over the 5-HT2C receptor and no significant affinity or activity at the 5-HT2B receptor or dopamine receptors .. mechanism of action. mechanism of action. inverse agonist. inverse agonist. serotonin. serotonin. affinity. affinity ( pharmacology ). activity. biological activity. The drug has met expectations for a Phase III clinical trial for the treatment of Parkinson 's disease psychosis , and has completed Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication .. psychosis. psychosis. schizophrenia. schizophrenia. Phase III. Phases of clinical research#Phase III. clinical trial. clinical trial. Phase II. Phases of clinical research#Phase II. adjunctive treatment. adjuvant therapy. antipsychotic. antipsychotic. Pimavanserin is expected to improve the effectiveness and side effect profile of antipsychotics .. effectiveness. efficacy. side effect. side effect. The results of a clinical trial examining the efficacy , tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012 , and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improved the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms .. clinical trial. clinical trial. antipsychotic. antipsychotic. risperidone. risperidone. haloperidol. haloperidol. extrapyramidal symptoms. extrapyramidal symptoms. On September 2 , 2014 , the United States Food and Drug Administration granted Breakthrough Therapy status to Acadia 's New Drug Application for pimavanserin .. United States. United States. Food and Drug Administration. Food and Drug Administration. Breakthrough Therapy. Breakthrough therapy. New Drug Application. New Drug Application. It was approved by the FDA to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson 's disease on April 29 , 2016 .. psychosis. psychosis